Dr Daigo's team

Member
Yataro Daigo, M.D., Ph.D.
Ryohei Nishino, M.D.
Junkichi Koinuma, M.D.
Nguyen Minh-Hue, MSc
Daiki Miki, M.D.
Ken Masuda, M.D.
Masato Aragaki, M.D.
Takashi Fujitomo, BSc
Rie Hayashi, BSc
Hiroe Fujiwara, MSc
Mika Kobayashi, BSc
Noriko Mizota
Mai Natsume, MSc
Hazuki Ichijo, BSc
Tae Nagao, BSc


Research Interests
Many genetic alterations associated with development and progression of human cancers have been reported, but the precise molecular mechanisms remain unclear. As the nature of cancer cells in individual patients is considered to be defined by their protein expression profiles, the systematic analysis of these profiles may provide information reflecting the detailed phenotypic and biological information about them. In this regard, recent progress in genome and proteome technology has enabled us to examine expression profiles of thousands of genes or proteins in a single experiment. Using our original cDNA microarray system containing 32,256 human genes and MALDI-TOF-MS/LC-MSn with high-throughput screening of tissue microarrays to analyze 1200 cases of archived clinical samples for validation of the potential target proteins, we are performing comprehensive gene and protein-expression profiles of several cancers. We believe that this effort will provide valuable information for eventually identifying diagnostic/predictive biomarkers and novel therapeutic target molecules for human cancers.
Fig. 1) The Principle of a cDNA microarray
Fig. 2 ) Development of new strategies for cancer therapy
Towards identification of molecules involved in the pathways of carcinogenesis, we are applying the microarray technology to several human cancers including lung cancer, esphageal cancer and osteosarcoma materials from surgical samples, cancer cell lines, tumor xenografts and metastasis model animals.

HGC｜ Inst. Med Sci.｜ Univ. Tokyo